Acquired Immune Deficiency Syndrome
14
1
1
6
Key Insights
Highlights
Success Rate
75% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 52/100
14.3%
2 terminated out of 14 trials
75.0%
-11.5% vs benchmark
29%
4 trials in Phase 3/4
33%
2 of 6 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 6 completed trials
Clinical Trials (14)
Dental Management of Patients With HIV in Pays de la Loire
WiseApp for Spanish Speakers Living With HIV
Immune Reconstitution of Lopinavir/Ritonavir-Based vs Efavirenz-based HAART in Advanced HIV Disease
A Pilot Study to Determine if Raltegravir Eradicates HIV From Peripheral Blood Mononuclear Cells
A Post Marketing Survey Study to Evaluate the Safety and Effectiveness of Prezista
A Post Marketing Survey Study to Evaluate the Safety and Effectiveness of Intelence
Pilot Study of a Raltegravir Based NRTI Sparing Regimen
Dose Optimisation of Stavudine for the Treatment of HIV Infection
Mentor Mothers: A Sustainable Family Intervention in South African Townships
Reactogenicity and Immunogenicity of Vaginal CNgp140
Correlation Between Cytokines and Hepatic Histology in Patients Infected by HIV-1 and the Hepatitis-C Virus
Study on the Antiviral Therapy and Immune Reconstitution of Chinese HIV/AIDS Patients
Influenza Vaccination at a Reduced Dose Using Mesotherapy in HIV/AIDS Patients at the Hadassah AIDS Center, Jerusalem
Safety and Efficacy of PRO 542 in the Treatment of HIV-Infected Patients